HK1206278A1 - Fused heterocyclic compounds as selective bmp inhibitors bmp - Google Patents

Fused heterocyclic compounds as selective bmp inhibitors bmp

Info

Publication number
HK1206278A1
HK1206278A1 HK15107024.8A HK15107024A HK1206278A1 HK 1206278 A1 HK1206278 A1 HK 1206278A1 HK 15107024 A HK15107024 A HK 15107024A HK 1206278 A1 HK1206278 A1 HK 1206278A1
Authority
HK
Hong Kong
Prior art keywords
bmp
heterocyclic compounds
selective
fused heterocyclic
inhibitors
Prior art date
Application number
HK15107024.8A
Other languages
English (en)
Chinese (zh)
Inventor
科里‧
‧霍普金
查爾斯‧
‧洪
克雷格‧
‧林斯利
達倫‧
‧恩格爾斯
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of HK1206278A1 publication Critical patent/HK1206278A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK15107024.8A 2012-09-28 2015-07-23 Fused heterocyclic compounds as selective bmp inhibitors bmp HK1206278A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261707661P 2012-09-28 2012-09-28
PCT/US2013/032588 WO2014051698A1 (fr) 2012-09-28 2013-03-15 Composés hétérocycliques condensés comme inhibiteurs sélectifs de bmp

Publications (1)

Publication Number Publication Date
HK1206278A1 true HK1206278A1 (en) 2016-01-08

Family

ID=50388847

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107024.8A HK1206278A1 (en) 2012-09-28 2015-07-23 Fused heterocyclic compounds as selective bmp inhibitors bmp

Country Status (13)

Country Link
US (2) US9738636B2 (fr)
EP (1) EP2900238B1 (fr)
JP (1) JP6430383B2 (fr)
KR (1) KR102092988B1 (fr)
CN (1) CN104768548B (fr)
AU (1) AU2013324396B2 (fr)
BR (1) BR112015007136A2 (fr)
CA (1) CA2886187C (fr)
DK (1) DK2900238T3 (fr)
ES (1) ES2660051T3 (fr)
HK (1) HK1206278A1 (fr)
SG (1) SG11201503299YA (fr)
WO (1) WO2014051698A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4066826B1 (fr) 2010-09-01 2024-03-06 Thomas Jefferson University Agonistes des récepteurs gamma de l'acide rétinoïque pour la réparation et la régénération musculaires
ES2750956T3 (es) 2014-02-13 2020-03-30 Incyte Corp Ciclopropilaminas como inhibidores de LSD1
SG11201606689VA (en) 2014-02-13 2016-09-29 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
WO2016007731A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines et imidazopyrazines à utiliser en tant qu'inhibiteurs de lsd1
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
NZ735998A (en) 2015-04-03 2024-08-30 Incyte Holdings Corp Heterocyclic compounds as lsd1 inhibitors
US10836742B2 (en) 2015-08-11 2020-11-17 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
CN108290856A (zh) 2015-08-11 2018-07-17 尼奥迈德研究所 芳基-取代的二氢喹诺酮、它们的制备和它们作为药物的用途
IL257340B2 (en) 2015-08-12 2023-10-01 Neomed Inst Converted benzaimidazoles, methods for their preparation and use as pharmaceuticals
NZ740186A (en) 2015-08-12 2024-07-05 Incyte Holdings Corp Salts of an lsd1 inhibitor
WO2017066876A1 (fr) 2015-10-21 2017-04-27 Neomed Institute Imidazopyridines substituées, leur préparation et leur utilisation comme médicaments
WO2017127930A1 (fr) * 2016-01-28 2017-08-03 Neomed Institute [1,2,4]triazolo[4,3-a]pyridines substituées, leur préparation et leur utilisation comme médicaments
EA201892497A1 (ru) 2016-06-08 2019-05-31 Клементиа Фармасьютикалз Инк. Способы лечения гетеротопической оссификации
TWI712598B (zh) * 2016-07-20 2020-12-11 瑞士商諾華公司 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
EP3512834A4 (fr) 2016-09-14 2020-05-06 Vanderbilt University Inhibition de la signalisation bmp, composés, compositions et leurs utilisations
WO2018136634A1 (fr) * 2017-01-18 2018-07-26 Vanderbilt University Composés hétérocycliques fusionnés en tant qu'inhibiteurs sélectifs de protéine morphogénétique osseuse (bmp)
EP3765460A1 (fr) 2018-03-14 2021-01-20 Vanderbilt University Inhibition de la signalisation bmp, composés, compositions et leurs utilisations
CN110496127A (zh) * 2018-05-17 2019-11-26 中国科学院上海生命科学研究院 一种热休克因子1的抑制剂、其制备方法和应用
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
EP3898627A1 (fr) * 2018-12-20 2021-10-27 Incyte Corporation Composés d'imidazopyridazine et d'imidazopyridine utilisés en tant qu'inhibiteurs de la kinase 2 de type récepteur de l'activine
US11738026B2 (en) 2019-11-22 2023-08-29 Incyte Corporation Combination therapy comprising an ALK2 inhibitor and a JAK2 inhibitor
KR20230025444A (ko) 2020-06-16 2023-02-21 인사이트 코포레이션 빈혈 치료를 위한 alk2 저해제
WO2024205336A1 (fr) * 2023-03-30 2024-10-03 에이치엘비생명과학알앤디 주식회사 Composition pharmaceutique présentant une activité inhibitrice de la tubuline

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2562071B1 (fr) * 1984-03-30 1986-12-19 Sanofi Sa Triazolo(4,3-b)pyridazines, procede pour leur preparation et compositions pharmaceutiques les contenant
GB9927687D0 (en) * 1999-11-23 2000-01-19 Merck Sharp & Dohme Therapeutic agents
JP4747396B2 (ja) 2000-05-17 2011-08-17 日立化成工業株式会社 接着剤組成物、それを用いた回路端子の接続方法及び回路端子の接続構造
CN100415744C (zh) * 2001-02-20 2008-09-03 阿斯特拉曾尼卡有限公司 用于治疗与gsk3有关的病症的2-芳基氨基-嘧啶
US7125888B2 (en) * 2002-05-02 2006-10-24 Merck & Co., Inc. Tyrosine kinase inhibitors
DOP2006000051A (es) * 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
EP2086973B1 (fr) * 2006-10-11 2012-01-25 Amgen Inc., Composés d'imidazo- et de triazolo-pyridine et leurs procédés d'utilisation
MX2009006704A (es) 2006-12-22 2009-06-30 Astex Therapeutics Ltd Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
WO2008078091A1 (fr) * 2006-12-22 2008-07-03 Astex Therapeutics Limited Composés hétérocycliques bicycliques servant d'inhibiteurs des fgfr
ES2320955B1 (es) * 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
CN101679422A (zh) * 2007-03-28 2010-03-24 阵列生物制药公司 作为受体酪氨酸激酶抑制剂的咪唑并[1,2-a]吡啶化合物
BRPI0809998B8 (pt) * 2007-04-03 2021-05-25 Array Biopharma Inc composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina quinase, seus usos, seus processos de preparação e composições farmacêuticas
EP2170882A1 (fr) * 2007-06-26 2010-04-07 Gilead Colorado, Inc. Inhibiteurs d'imidazopyridinyl-thiazolyl-histone désacétylase
ATE522249T1 (de) 2007-07-26 2011-09-15 Novartis Ag Organische verbindungen
US8367662B2 (en) * 2007-10-17 2013-02-05 Novartis Ag Organic compounds
CA2718403A1 (fr) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibiteurs de la voie de signalisation bmp
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
US8575337B2 (en) 2008-06-24 2013-11-05 Research Foundation Itsuu Laboratory Oxazolidinone derivative having fused ring
WO2010083145A1 (fr) * 2009-01-16 2010-07-22 Merck Sharp & Dohme Corp. Imidazo[1,2-a]pyridines et imidazo[1,2-b]pyridazines utilisés en tant qu'inhibiteurs de la kinase mark
JP2012521354A (ja) * 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
CN102971326A (zh) * 2010-04-28 2013-03-13 百时美施贵宝公司 咪唑并哒嗪化合物及其在癌症中的用途
TW201144310A (en) 2010-04-28 2011-12-16 Daiichi Sankyo Co Ltd [5,6] heterocyclic compound
WO2012088266A2 (fr) 2010-12-22 2012-06-28 Incyte Corporation Imidazopyridazines et benzimidazoles substitués en tant qu'inhibiteurs de fgfr3
US9505763B2 (en) * 2011-07-25 2016-11-29 Vanderbilt University Cancer treatment using BMP inhibitor
EP2615151A1 (fr) 2011-12-23 2013-07-17 Services Pétroliers Schlumberger Compositions et procédés pour la cimentation des puits
EP2964651A4 (fr) * 2013-03-04 2016-11-30 Brigham & Womens Hospital Inhibiteurs de bmp et leurs procédés d'utilisation
US9682983B2 (en) * 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof

Also Published As

Publication number Publication date
US10196392B2 (en) 2019-02-05
KR102092988B1 (ko) 2020-03-25
US9738636B2 (en) 2017-08-22
JP2015531371A (ja) 2015-11-02
KR20150064137A (ko) 2015-06-10
EP2900238A1 (fr) 2015-08-05
AU2013324396A1 (en) 2015-05-14
US20160068525A1 (en) 2016-03-10
US20170313701A1 (en) 2017-11-02
CN104768548A (zh) 2015-07-08
SG11201503299YA (en) 2015-06-29
EP2900238B1 (fr) 2017-12-06
ES2660051T3 (es) 2018-03-20
JP6430383B2 (ja) 2018-11-28
WO2014051698A1 (fr) 2014-04-03
EP2900238A4 (fr) 2016-04-06
AU2013324396B2 (en) 2018-10-04
BR112015007136A2 (pt) 2018-05-15
DK2900238T3 (en) 2018-03-12
CA2886187C (fr) 2020-04-14
CA2886187A1 (fr) 2014-04-03
CN104768548B (zh) 2018-08-10

Similar Documents

Publication Publication Date Title
HK1206278A1 (en) Fused heterocyclic compounds as selective bmp inhibitors bmp
HK1212693A1 (zh) 作為溴結構域抑制劑的新的雜環化合物
EP2862853A4 (fr) Composé hétérocyclique fusionné
EP2865671A4 (fr) Composé hétérocyclique fusionné
EP2857396A4 (fr) Composé hétérocyclique condensé
EP2857397A4 (fr) Composé hétérocyclique condensé
HK1210769A1 (en) Heterocyclic compound
ZA201406078B (en) Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhibitors
ZA201303801B (en) Fused aminodihydrothiazine derivatives useful as bace inhibitors
EP2889291A4 (fr) Composé hétérocyclique
EP2832734A4 (fr) Composé hétérocyclique
EP2873669A4 (fr) Composé hétérocyclique
EP2865672A4 (fr) Composé hétérocyclique fusionné
EP2709609A4 (fr) Composés hétérocycliques
ME02576B (fr) Inhibiteurs de bace
EP2818473A4 (fr) Composé hétérocyclique
HK1201521A1 (en) Heterocyclic compounds and methods for their use
EP2857400A4 (fr) Composé hétérocyclique
HK1201533A1 (en) Heterocyclic compounds and methods for their use
HK1201531A1 (en) Heterocyclic compounds and methods for their use
EP2927229A4 (fr) Composé hétérocyclique
EP2940013A4 (fr) Composé hétérocyclique substitué par un halogène
EP2866893A4 (fr) Inhibiteurs d' atpase de type f1f0, à base de guanidine hétérocyclique et leurs utilisations thérapeutiques
GB201202400D0 (en) Nitrogen-containing heterocyclic compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20230321